Sign In

Gregory B. Lesinski PhD

Gregory B. Lesinski PhD
Asst ProfessorCollege of Medicinegregory.lesinski@osumc.edu
302B Wiseman Hall 400 W 12th Avenue Columbus OH 43210
Phone:614-292-3676Fax:
  • Molecular Carcinogenesis and Chemoprevention

General Research Interest

Immunotherapy, Experimental Therapeutics, Melanoma, Immunomodulatory effects of natural products.

Research Description

Dr. Lesinski’s research is focused on gaining a greater understanding of the interactions between the host immune system and tumor cells. The ultimate goal is to use this knowledge to develop novel therapeutic or chemo-preventative approaches to help patients with cancer, and improve upon existing therapies. Of particular interest are inhibition of the oncogenic STAT3 pathway and maximizing the effect of immune based therapy.

Transinstitutional Work

Dr. Lesinski is collaborating with numerous members of the OSU CCC in conducting correlative laboratory studies for human clinical trials involving immune-based therapies.  He is a long-time collaborator with his former mentor, Dr. William E. Carson, III investigating the role of microRNA in melanoma and how immune stimulating cytokines elicit anti-tumor activity.  Dr. Lesinski is a member of the multidisciplinary Molecular Targeted Therapy (MTT) group, led by Dr. Pui Kai-Li, who are developing novel small molecule inhibitors of pro-oncogenic pathways in tumor cells.  Finally, Dr. Lesinski is working in collaboration with Dr. Steve Clinton to examine how natural products with chemopreventative activity modulate immune function.

Current Publications

  • Mace TA, Collins AL, Wojcik SE, Croce CM, Lesinski GB, Bloomston MHypoxia induces the overexpression of microRNA-21 in pancreatic cancer cells.J Surg Res in press 5/18/2013
  • Mace TA, Ameen Z, Collins A, Wojcik SE, Mair M, Young GS, Fuchs JR, Eubank TD, Frankel WL, Bekaii-Saab T, Bloomston M, Lesinski GBPancreatic Cancer-Associated Stellate Cells Promote Differentiation of Myeloid-Derived Suppressor Cells in a STAT3-Dependent Manner.Cancer Res 73(10) 3007-18 5/15/2013
  • Gaudio E, Paduano F, Ngankeu A, Lovat F, Fabbri M, Sun HL, Gasparini P, Efanov A, Peng Y, Zanesi N, Shuaib MA, Rassenti LZ, Kipps TJ, Li C, Aqeilan RI, Lesinski GB, Trapasso F, Croce CMHeat shock protein 70 regulates Tcl1 expression in leukemia and lymphomas.Blood 121(2) 351-9 1/10/2013
  • Sullivan NJ, Tober KL, Burns EM, Schick JS, Riggenbach JA, Mace TA, Bill MA, Young GS, Oberyszyn TM, Lesinski GBUV light B-mediated inhibition of skin catalase activity promotes Gr-1+ CD11b+ myeloid cell expansion.J Invest Dermatol 132(3 Pt 1) 695-702 3/1/2012
  • Bill MA, Nicholas C, Mace TA, Etter JP, Li C, Schwartz EB, Fuchs JR, Young GS, Lin L, Lin J, He L, Phelps M, Li PK, Lesinski GBStructurally modified curcumin analogs inhibit STAT3 phosphorylation and promote apoptosis of human renal cell carcinoma and melanoma cell lines.PLoS One 7(8) e40724 1/1/2012
  • Lemeshow S, Sørensen HT, Phillips G, Yang EV, Antonsen S, Riis AH, Lesinski GB, Jackson R, Glaser Rβ-Blockers and survival among Danish patients with malignant melanoma: a population-based cohort study.Cancer Epidemiol Biomarkers Prev 20(10) 2273-9 10/1/2011
  • Grignol V, Fairchild ET, Zimmerer JM, Lesinski GB, Walker MJ, Magro CM, Kacher JE, Karpa VI, Clark J, Nuovo G, Lehman A, Volinia S, Agnese DM, Croce CM, Carson WE 3rdmiR-21 and miR-155 are associated with mitotic activity and lesion depth of borderline melanocytic lesions.Br J Cancer 105(7) 1023-9 9/27/2011
  • Mundy-Bosse BL, Young GS, Bauer T, Binkley E, Bloomston M, Bill MA, Bekaii-Saab T, Carson WE 3rd, Lesinski GBDistinct myeloid suppressor cell subsets correlate with plasma IL-6 and IL-10 and reduced interferon-alpha signaling in CD4⁺ T cells from patients with GI malignancy.Cancer Immunol Immunother 60(9) 1269-79 9/1/2011
  • Guenterberg KD, Lesinski GB, Mundy-Bosse BL, Karpa VI, Jaime-Ramirez AC, Wei L, Carson WE 3rdEnhanced anti-tumor activity of interferon-alpha in SOCS1-deficient mice is mediated by CD4⁺ and CD8⁺ T cells.Cancer Immunol Immunother 60(9) 1281-8 9/1/2011
  • Mundy-Bosse BL, Lesinski GB, Jaime-Ramirez AC, Benninger K, Khan M, Kuppusamy P, Guenterberg K, Kondadasula SV, Ray Chaudhury A, La Perle KM, Kreiner M, Young GS, Guttridge DC, Carson WEMyeloid-derived suppressor cell inhibition of the IFN response in tumor-bearing mice.Cancer Res 71(15) 5101-10 8/1/2011